Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida.
Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida.
Transplant Cell Ther. 2022 Jan;28(1):5-17. doi: 10.1016/j.jtct.2021.10.005. Epub 2021 Oct 14.
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the Western hemisphere. The recent availability of novel targeted therapies, namely Bruton's tyrosine kinase, phosphoinositide-3 kinase, and BCL-2 inhibitors, have revolutionized the treatment algorithm for CLL but have not yet resulted in cure. Advances in the field of immuno-oncology and T cell engineering brought chimeric antigen receptor (CAR) T cell therapy from the laboratory to the clinic for treatment of B cell lymphoid malignancies and has improved the disease response and survival outcomes of various types of relapsed and/or refractory B cell lymphomas. While acknowledging that there are no approved CAR T cell therapies for CLL at this time, in this comprehensive review we explore novel targets for CAR T cell therapy in CLL and highlight the promising results of CAR T cell trials reported to date. Furthermore, we shed light on future areas of development, including multitarget CAR T cell products for this disease.
慢性淋巴细胞白血病（CLL）是西半球最常见的白血病。新型靶向治疗药物（如 Bruton 酪氨酸激酶抑制剂、磷脂酰肌醇 3 激酶抑制剂和 BCL-2 抑制剂）的出现彻底改变了 CLL 的治疗方案，但尚未实现治愈。免疫肿瘤学和 T 细胞工程领域的进展将嵌合抗原受体（CAR）T 细胞疗法从实验室推向临床，用于治疗 B 细胞淋巴瘤恶性肿瘤，并改善了各种复发和/或难治性 B 细胞淋巴瘤的疾病反应和生存结果。虽然目前尚无针对 CLL 的获批 CAR T 细胞疗法，但在本次全面综述中，我们探讨了 CLL 中 CAR T 细胞治疗的新靶点，并强调了迄今为止报道的 CAR T 细胞试验的有前景结果。此外，我们还探讨了未来的发展领域，包括针对这种疾病的多靶点 CAR T 细胞产品。
